

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented) A method for making a composition containing a peptide salt having a pharmaceutically acceptable anion comprising:

contacting a first peptide salt with a diluent to form a diluent solution;

contacting the diluent solution containing the first peptide salt with a mixed bed ion exchanger, wherein the mixed bed ion exchanger has strongly acidic cations and strong anion exchangers;

separating the mixed bed ion exchanger from the diluent solution;

contacting the diluent solution with an acid having a pharmaceutically acceptable anion, thereby forming an acid addition salt of the peptide having the pharmaceutically acceptable anion;

adding an adjuvant to the diluent solution; and

separating the diluent from the diluent solution.

Claim 2 (previously presented) The method of claim 1, wherein the first peptide salt is a salt of an LHRH antagonist selected from the group of Cetrorelix, Teverelix, Abarelix, Ganirelix, Azalinc B, Antide, A-75998, Detirelix, Ramorelix, and RS-68439.

Claim 3 (previously presented) The method of claim 1, wherein said acid is embonic acid, stearic acid, or salicylic acid.

Claim 4 (previously presented) The method of claim 1, wherein the first peptide salt is Cetrorelix acetate, and said acid is embonic acid, and the peptide:acid molar ratio is 2:1.

Claim 5 (previously presented) The method of claim 1, wherein said acid addition salt of the peptide is separated from the diluent by freeze drying.

Claim 6-12 (cancelled)